Coronary Microvascular Function and CT Coronary Angiography (CorCTCA)

Study Overview
=================
Brief Summary
-----------------
Angina in patients without obstructive coronary artery disease (CAD) is a clinical conundrum and patient management is heterogeneous. Hypothesis: Abnormal coronary function is common and clinically relevant in this population. Design: An observational cohort study and nested randomised controlled diagnostic strategy trial. Methods: 250 patients with known or suspected angina informed by validated questionnaires but without obstructive CAD (<70% stenosis) in an artery >=2.5 mm or structural heart disease, as revealed by CT coronary angiography (CTCA), will be invited to undergo coronary function testing (FFR, CFR, IMR; intra-coronary ACh) during invasive angiography. Patients will be randomised following angiography but before testing coronary function to disclosure of the coronary function test results or not. Treatment decisions by the attending cardiologist will be recorded before and after disclosure of results. Outcomes: Primary: The between-group difference in the reclassification rate of the initial diagnosis using logistic regression, adjusted for baseline factors associated with the likelihood of reclassification of the initial diagnosis. Secondary: Prevalence of microvascular or vasospastic angina; health status reflected by the EuroQol group 5-Dimensions (EQ-5D), Seattle Angina Questionnaire, Illness perception, treatment satisfaction questionnaires and functional status questionnaires; angina medication and adherence. Value: This research will provide new insights into the conundrum of angina in patients without obstructive CAD or structural heart disease.

Detailed Description
-----------------
According to information provided by the British Heart Foundation, there are approximately 2.3 million men and women living with angina in the United Kingdom (UK). In 2014, there were  247,363 coronary angiograms performed, mostly for the investigation of known or suspected angina, but only about half of the patients have obstructive coronary artery disease (CAD) identified by the angiogram. Considering CT coronary angiography (CTCA), <=1 in 4 patients referred to the Chest Pain Clinic with chest pain of suspected cardiac origin have obstructive CAD identified by the CTCA scan. The explanation for the cause(s) of the chest pain are often unclear, which can be frustrating to patients and clinicians. Small vessel disease, i.e. microvascular or vasospastic angina may be one explanation. Anatomical imaging of the coronary arteries non-invasively by CTCA or invasively is an insensitive approach for the assessment of coronary function, and even visual assessment of the angiogram for obstructive CAD by invasive angiography or CTCA, may sometimes lead to mis-diagnosis and sub-optimal outcomes. Novel adjunctive tests of coronary function may have incremental diagnostic value to further inform medical decisions. Taken together, the literature and practice guidelines suggest a clinical problem of unmet need, with the potential for benefits to patients and healthcare providers if the diagnostic management can be improved. Our proposal addresses the evidence gap, by exploiting advances in diagnostic tests to gather information on the prevalence of microvascular and vasospastic disorders in patients with angina in whom obstructive CAD has been ruled out. By implementing a diagnostic management strategy in the context of a randomised, blinded, controlled trial, the investigators aim to determine whether use of coronary function tests in relevant patients might be beneficial. Angina in patients without obstructive CAD and insights from contemporary clinical trials: The Fractional Flow Reserve versus Angiography for Multivessel Evaluation 2 (FAME-2), Scottish COmputed Tomography of the HEART (SCOT-HEART), Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE), and Clinical Evaluation of Magnetic Resonance Imaging in Coronary Heart Disease 2 (CE-MARC 2) 2 trials focused on the diagnosis and treatment of angina due to obstructive CAD. Paradoxically, the findings in these trials have diagnosed considerable numbers of patients with angina without obstructive CAD. In FAME-2, of 1220 patients with stable CAD, 332 (27%) had non-flow limiting (FFR>0.80) CAD. The distribution of the Canadian Cardiovascular Society angina classes was similar between the randomised patients and those in the registry (p=0.64), as was the prevalence of silent ischaemia (16%; p=0.96). The registry patients were treated with medical therapy and the MACE rate was 9% at 2 years. In SCOT-HEART, of 4146 patients with suspected angina assessed at the Chest Pain Clinic, 2450 (59%) had confirmed angina (typical or atypical), yet considering the prevalence of obstructive CAD as revealed by CTCA (>70% stenosis in ≥1 major branches or 50% in the left main stem), just 25% had obstructive CAD. In the PROMISE trial, 10,003 participants (n=8939 (89.4%) with typical or atypical angina) were randomised to a strategy of initial anatomical testing with CTCA or to a strategy of functional testing (exercise ECG or stress imaging). Using similar diagnostic criteria as in SCOT-HEART, only 517 (10.7%) of the 4996 participants in the CTCA group had a 'positive' result. No further data were provided to explain the aetiology of the angina in the patients without obstructive CAD. Most recently, the CE-MARC 2 trial compared diagnostic strategies in patients referred to the Chest Pain Clinic with a pre-test likelihood of CAD of 10% to 90%. All (n=1202) of the participants had a history of angina, with 401 (33.4%) having typical angina. Only a minority of participants had a positive non-invasive test (12.4% in the CMR group, 18.2% in the myocardial perfusion scintigraphy (MPS) group and 13.4% in the NICE Guideline group). Invasive coronary angiography was performed within 12 months of randomisation in 265 (22%) patients. The primary outcome of unnecessary angiography (defined as an FFR>0.8 or quantitative coronary analysis showing no stenosis ≥70% in 1 view or ≥50% in 2 orthogonal views in all coronary vessels ≥2.5 mm diameter), occurred in 139 subjects (12%): 7.5% in the CMR group, 7.1% in the MPS group and 28.8% of participants in the NICE guidelines group. CEMARC 2 was a pragmatic trial and since invasive angiography was not performed in all of the subjects, the causes of the angina in patients with 'negative' non-invasive imaging tests were unclear. Finally, the ISCHEMIA trial investigators have observed that some of the participants enrolled with moderate-severe myocardial ischemia on stress testing (% left ventricular (LV) mass) do not have obstructive CAD. The Changes in Ischemia and Angina over One year among ISCHEMIA trial screen failures with no obstructive coronary artery disease on coronary CT angiography (CIAO-ISCHEMIA) study has been instigated to investigate these patients in greater detail. In the SCOT-HEART trial, symptoms and quality of life assessed at baseline and 6 months improved less in patients assigned to the CTCA-guided strategy as compared to standard care. This analysis refuted the hypothesis that symptoms and quality of life would improve with a CTCA-guided strategy and it conflicts with the NICE-95 guideline recommendations. Patients in the CTCA group with a change in diagnosis confirming obstructive CAD or excluding CAD had the greatest improvement in symptoms. By contrast, patients with non-obstructive CAD had the least improvement in symptoms. There could be several reasons to explain this finding. Firstly, patient satisfaction may be greater with a definitive diagnosis and treatment plan i.e. 1) normal coronaries - stop treatment, 2) obstructive CAD - percutaneous coronary intervention (PCI) or coronary artery bypass surgery (CABG), while a result of intermediate CAD with no change in treatment may result in lower patient satisfaction. Secondly, a false negative CTCA result may have occurred in some patients with flow limiting CAD (since objective assessments of flow limiting CAD and/or ischaemia were not performed). Finally, some patients with non-obstructive CAD may have had microvascular disease. Since clinicians may have stopped angina treatment in patients without obstructive CAD, the symptoms of patients who had microvascular angina (and a negative CTCA scan) may have deteriorated. The design of our study includes a multicentre, observational study involving novel diagnostic tests of coronary function in order to provide information on the prevalence of microvascular and/or vasospastic disease in patients with angina but non obstructive CAD as revealed by CTCA. The CTCA protocol will be undertaken according optimal standards i.e. heart rate control with beta-blocker medication, administration of sublingual nitrate before the CTCA scan, etc. The clinical relevance of additional tests of coronary function will be assessed through a nested randomised strategy trial of management (diagnosis and treatment) guided by the coronary function test results versus standard care guided by angiography. The possibility of occasional CAD misclassification by CTCA (i.e. false negative, obstructive CAD) will also be assessed. Follow-up will include assessments of health, well-being and treatment satisfaction. The wider adoption of anatomical imaging with CTCA as a first-line diagnostic test for the assessment of stable chest pain (NICE-95 guideline update, November 2016), supports the rationale for this research.

Official Title
-----------------
Angina in Patients Without Obstructive Coronary Disease as Revealed by CT Coronary Angiography (Cor-CTCA): an Observational Cohort Study Involving Coronary Function Tests and a Nested Randomised Trial

Conditions
-----------------
Angina, Stable, Angina Pectoris, Variant, Microvascular Angina

Intervention / Treatment
-----------------
* Diagnostic Test: Stratified medicine involving a diagnostic intervention
* Diagnostic Test: Stratified medicine involving a diagnostic intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Symptoms of angina or angina-equivalent informed by the Rose Angina questionnaire. Intermediate or no obstructive coronary disease i.e. no coronary stenosis >70% in an artery >2.5 mm, as revealed by CT coronary angiography. Exclusion Criteria: A health problem that would explain the angina, e.g. anaemia, moderate-severe aortic stenosis, hypertrophic obstructive cardiomyopathy Obstructive disease evident in a coronary artery (diameter >2.5 mm), i.e. >50 - 70% circumferential plaque extending for ≥2 coronary segments, or a stenosis>70% as revealed by CT coronary angiography Lack of informed consent. Exclusion from randomisation in the catheter laboratory: Flow-limiting coronary disease defined by a fractional flow reserve (FFR) ≤0.80 in an artery>2.5 mm.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Randomized, double-blind, parallel group, prospective
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Intervention group (coronary function test results disclosed)<br>Coronary function tests are measured and disclosed to the clinician for re-evaluation of the initial diagnosis and treatment as compared with initial angiography. The intervention involves measurement of FFR, CFR, IMR and RRR in a major coronary artery followed by reactivity testing using incremental doses of acetylcholine (10-4 Molar (M), 10-5 M, 10-6 M) to assess endothelial function, bolus of ACh (10-4 M; 100 micrograms) for vasospasm, followed by glyceryl trinitrate (300 micrograms). FFR will be measured in all arteries with a diameter >=2.5 mm and a stenosis 40% to 90% in severity. Endotypes are based on criteria for abnormal coronary vasodilator function, vasospasm and microvascular resistance. The endotypes (diagnostic strata) are: obstructive CAD, vasospastic angina, microvascular angina, mixed (ie both vasospastic and microvascular disorders), endothelial dysfunction (no angina), normal (non-cardiac). A diagnosis may be ruled-in or ruled-out based on the test results. | Diagnostic Test: Stratified medicine involving a diagnostic intervention<br>* Adjunctive tests of coronary artery lesion severity (fractional flow reserve) and function at the time of invasive coronary angiography. Diagnostic groups: stable coronary syndromes in patients with obstructive coronary artery disease (mis-classified by non-invasive CTCA) or no-obstructive coronary disease including the following sub-groups (coronary artery vasospasm, microvascular spasm, impaired vasorelaxation due to (1) endothelial dysfunction and/or (2) non-endothelial dysfunction, or unaffected (normal test results). Medical management is linked to contemporary clinical guidelines for the management of patients with stable coronary artery disease (European Society of Cardiology (2013), Scottish Intercollegiate Guideline Network (SIGN), 2017).<br>* Other names: Adjunctive tests of coronary disease severity and function (disclosed);|
| Sham Comparator: Usual care group (coronary function results not disclosed)<br>Coronary function tests are measured but not disclosed to the attending clinician or the participant. The same coronary function tests are undertaken as in the intervention group. Masking is achieved by obscuring the catheter laboratory monitors from the attending clinician and participant. The effectiveness of masking and protocol adherence is prospectively monitored. | Diagnostic Test: Stratified medicine involving a diagnostic intervention<br>* Adjunctive tests of coronary artery lesion severity (fractional flow reserve) and function at the time of invasive coronary angiography. Diagnostic groups: stable coronary syndromes in patients with obstructive coronary artery disease (mis-classified by non-invasive CTCA) or non-obstructive coronary disease including the following sub-groups (coronary artery vasospasm, microvascular spasm, impaired vasorelaxation due to (1) endothelial dysfunction and/or (2) non-endothelial dysfunction, or unaffected (normal test results). Medical management is linked to contemporary clinical guidelines for the management of patients with stable coronary artery disease (European Society of Cardiology (2013), Scottish Intercollegiate Guideline Network (SIGN), 2017).<br>* Other names: Adjunctive tests of coronary disease severity and function (not disclosed, sham control);|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Final diagnosis | The between-group difference in the reclassification rate of the initial diagnosis based on CTCA vs. final diagnosis after the invasive procedure involving coronary function tests in a a major coronary artery using logistic regression, adjusted for baseline factors associated with the likelihood of reclassification of the initial diagnosis. | Day 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurrence of abnormal coronary function in a major epicardial coronary artery | To determine the prevalence of microvascular and/or vasospastic angina at the end of the invasive diagnostic procedure (including the coronary angiogram and coronary function tests) in the study population defined as having non obstructive artery disease (CAD) or none as revealed by a CT coronary angiogram for the investigation of known or suspected CAD. | Day 1 | 
| Presence of an obstructive or flow-limiting stenosis in a major coronary artery. | Assess the prevalence of obstructive CAD (e.g. FFR≤0.80) at the time of invasive coronary angiography. | Day 1 | 
| Procedure-related serious adverse events | Safety as reflected by the occurrence of procedure-related serious adverse events | Day 1 | 
| Prevalence of endotypes | Diagnosis of endotypes (disease strata): obstructive CAD, coronary vasospastic angina, microvascular angina, endothelial dysfunction (no angina), normal (non-cardiac, normal coronary function results, no angina). | Day 1 | 
| Cardiovascular risk | Assess the cardiovascular risk of the participants at baseline, as reflected by the validated JBS3 risk score http://www.jbs3risk.com/ | Day 1 | 
| Anxiety and depression | Assess the participants' self-reported levels of anxiety and depression using the Patient Health Questionnaire-4, a 4 item inventory rated on a 4 point Likert-type scale (0-3 per item, with a maximum reported score of 6 for anxiety and 6 for depression). | Through study completion, 3 years | 
| Treatment satisfaction | Assess the participants' self-reported levels of treatment satisfaction using the Treatment Satisfaction Questionnaire for Medication (TSQM) (scale categories, 2 to 7; a higher response reflects higher treatment satisfaction). | Through study completion, 3 years | 
| Illness perception | Assess the participants' perception of their illness using the Brief Illness Perception Questionnaire, a 9 item scale reflecting the cognitive and emotional representations of illness. Each item is analysed individually. | Through study completion, 3 years | 
| Health status EQ-5D | Assess the participants' general health status and self reported quality of life using the EQ5D questionnaire. Health status is measured in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression (each is scored on a scale of 1 to 5, with a score of 5 representing the most severe problems or limitations). The visual analog scale ranges from 0 to 100 units, with higher values representing a better outcome. | Through study completion, 3 years | 
| Health status (Seattle Angina Score) | Health status and symptoms will be assessed at baseline and again at 6 months, 12 months and closeout using the Seattle Angina Questionnaire. The secondary outcome is the within-subject change in Seattle Angina Score score over time. | Through study completion, 3 years | 
| Functional status | To assess functional status and activity levels as reflected by the Duke Activity Status Index (DASI) at baseline and during follow-up. | Through study completion, 3 years | 
| Health economics | Assess resource utilisation including primary and secondary care costs for tests, procedures and outpatient visits, and medicines, between the randomised groups | 36 months | 
| Serum troponin concentration | Assess associations between circulating concentrations of troponin I protein (ng/L) that may be implicated in the pathophysiology of disorders of coronary function. | Through study completion, 3 years | 
| Physical activity | To assess physical activity levels as reflected by the International Physical Activity Questionnaire - Short Form (IPAQ-SF) with units of activity expressed in minutes/week at baseline and during follow-up. Patients are classified as inactive, moderately active, or HEPA (health-enhancing physical activity) active, depending on how much vigorous/moderate/light exercise they do in a week. | Through study completion, 3 years | 
| Plasma endothelin-1 | Assess the circulating concentration of big endothelin-1 (pg/mL) peptide in plasma at sampling time-points, baseline and during follow-up. Big endothelin-1 is the stable pre-cursor of endothelin-1 and big endothelin-1 is more stable than endothelin-1 so the former is intended to be measured. | Through study completion, 3 years |